Novel treatments for vasospasm after subarachnoid hemorrhage

Current Opinion in Critical Care

Volumn 18, Issue 2, 2012, Pages 119-126

  Muroi, Carl ^a,b   Seule, Martin ^a   Mishima, Kenichi ^b   Keller, Emanuela ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b FUKUOKA UNIVERSITY   (Japan)

Author keywords

cerebral vasospasm; delayed cerebral ischemia; subarachnoid hemorrhage; treatment

Indexed keywords

CLAZOSENTAN; DANTROLENE; ERYTHROPOIETIN; FASUDIL; GLYCERYL TRINITRATE; HERBACEOUS AGENT; HUMAN ALBUMIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAGNESIUM SULFATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICARDIPINE; NIMODIPINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PAPAVERINE; PLACEBO; PRAVASTATIN; SILDENAFIL; SIMVASTATIN; SODIUM NITRATE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; VERAPAMIL;

ANEMIA; BRADYCARDIA; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN VASOSPASM; CONTINUOUS INFUSION; DELAYED CEREBRAL ISCHEMIA; DELAYED CEREBRAL ISCHEMICA; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG PELLET; HEMODILUTION; HEMODYNAMICS; HUMAN; HYPERTENSION; HYPERVOLEMIA; HYPOCALCEMIA; HYPOTENSION; KINETIC THERAPY; LIVER FUNCTION; LUMBAR DRAINAGE; LUNG DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVIEW; SIDE EFFECT; SPREADING CORTICAL DEPRESSION; SUBARACHNOID HEMORRHAGE; SURGICAL DRAINAGE; THERAPY;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; CRITICAL CARE; DIOXANES; FEMALE; HUMANS; HYPERTENSION; MAGNESIUM SULFATE; MALE; PYRIDINES; PYRIMIDINES; SUBARACHNOID HEMORRHAGE; SULFONAMIDES; TETRAZOLES; VASOSPASM, INTRACRANIAL;

EID: 84858794741     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32835075ae     Document Type: Review

References (53)

1. Rabinstein AA, Lanzino G, Wijdicks EF. Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage. Lancet Neurol 2010; 9:504-519.
2. Samuels O, Webb A, Culler S, et al. Impact of a dedicated neurocritical care team in treating patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care 2011; 14:334-340.
3. Rinkel GJ, Algra A. Long-term outcomes of patients with aneurysmal subarachnoid haemorrhage. Lancet Neurol 2011; 10:349-356.
4. Lovelock CE, Rinkel GJ, Rothwell PM. Time trends in outcome of subarachnoid hemorrhage: population-based study and systematic review. Neurology 2010; 74:1494-1501.
5. Castanares-Zapatero D, Hantson P. Pharmacological treatment of delayed cerebral ischemia and vasospasm in subarachnoid hemorrhage. Ann Intensive Care 2011; 1:12.
6. Vergouwen MD. Vasospasm versus delayed cerebral ischemia as an outcome event in clinical trials and observational studies. Neurocrit Care 2011; 15:308-311.
7. Vergouwen MD, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke 2010; 41:2391-2395.
8. Vergouwen MD, Ilodigwe D, Macdonald RL. Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and -independent effects. Stroke 2011; 42:924-929.
9. Sehba FA, Pluta RM, Zhang JH. Metamorphosis of subarachnoid hemorrhage research: from delayed vasospasm to early brain injury. Mol Neurobiol 2011; 43:27-40.
10. Dreier JP. The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. Nat Med 2011; 17:439-447.
11. Leng LZ, Fink ME, Iadecola C. Spreading depolarization: a possible new culprit in the delayed cerebral ischemia of subarachnoid hemorrhage. Arch Neurol 2011; 68:31-36.
12. Muroi C, Mink S, Seule M, et al. Monitoring of the inflammatory response after aneurysmal subarachnoid haemorrhage in the clinical setting: review of literature and report of preliminary clinical experience. Acta Neurochir Suppl 2011; 110:191-196.
13. Nakura T, Osuka K, Inukai T, et al. Soluble gp130 regulatess interleukin-6 in cerebrospinal fluid after subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2011; 82:952-954.
14. Sarrafzadeh A, Schlenk F, Gericke C, Vajkoczy P. Relevance of cerebral interleukin-6 after aneurysmal subarachnoid hemorrhage. Neurocrit Care 2010; 13:339-346.
15. Edvinsson L, Povlsen GK. Late cerebral ischaemia after subarachnoid haemorrhage: Is cerebrovascular receptor upregulation the mechanism behind? Acta Physiol (Oxf) 2011; 203:209-224.
16. Crowley RW, Medel R, Dumont AS, et al. Angiographic vasospasm is strongly correlated with cerebral infarction after subarachnoid hemorrhage. Stroke 2011; 42:919-923.
17. Vergouwen MD, Etminan N, Ilodigwe D, Macdonald RL. Lower incidence of cerebral infarction correlates with improved functional outcome after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 2011; 31:1545-1553.
18. Macdonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 2011; 10:618-625.
19. Macdonald RL, Higashida RT, Keller E, et al. Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials. Neurocrit Care 2010; 13:416-424.
20. Suarez JI. Magnesium sulfate administration in subarachnoid hemorrhage. Neurocrit Care 2011; 15:302-307.
21. Wong GK, Poon WS, Chan MT, et al. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial. Stroke 2010; 41:921-926.
22. DiringerMN, Bleck TP, Claude Hemphill J 3rd, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the neurocritical care society's multidisciplinary consensus conference. Neurocrit Care 2011; 15:211-240.
23. Vergouwen MD. Magnesium sulfate for aneurysmal subarachnoid hemorrhage: the end of the road or more trials? Crit Care 2011; 15:140.
24. Keller E, Muroi C. Magnesium sulfate for subarachnoid hemorrhage: a piece of the mosaic. Stroke 2010; 41:e576.
25. Fathi AR, Bakhtian KD, Pluta RM. The role of nitric oxide donors in treating cerebral vasospasm after subarachnoid hemorrhage. Acta Neurochir Suppl 2011; 110:93-97.
26. Fathi AR, Pluta RM, Bakhtian KD, et al. Reversal of cerebral vasospasm via intravenous sodium nitrite after subarachnoid hemorrhage in primates. J Neurosurg 2011; 115:1213-1220.
27. Pluta RM, Oldfield EH, Bakhtian KD, et al. Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. PLoS One 2011; 6:e14504.
28. Tseng MY. Summary of evidence on immediate statins therapy following aneurysmal subarachnoid hemorrhage. Neurocrit Care 2011; 15:298-301.
29. Liu GJ, Wang ZJ, Wang YF, et al. Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. Eur J Clin Pharmacol 2011. doi 10.1007/s00228-011-1100-x.
30. Suarez JI, Martin RH. Treatment of subarachnoid hemorrhage with human albumin: ALISAH study. Rationale and design. Neurocrit Care 2010; 13:263-277.
31. Han BH, Vellimana AK, Zhou ML, et al. Phosphodiesterase 5 inhibition attenuates cerebral vasospasm and improves functional recovery after experimental subarachnoid hemorrhage. Neurosurgery 2012; 70:178-187.
32. Muehlschlegel S, Rordorf G, Sims J. Effects of a single dose of dantrolene in patients with cerebral vasospasm after subarachnoid hemorrhage: a prospective pilot study. Stroke 2011; 42:1301-1306.
33. Tseng MY, Hutchinson PJ, Kirkpatrick PJ. Interaction of neurovascular protection of erythropoietin with age, sepsis, and statin therapy following aneurysmal subarachnoid hemorrhage. J Neurosurg 2010; 112:1235-1239.
34. Lee HC, Hsieh CL, Chen CC, et al. A pilot study in acute subarachnoid haemorrhagic patients after aneurysm clipping with complementary therapies of Chinese medicine. Complement Ther Med 2010; 18:191-198.
35. Wang HC, Lin WC, Yang TM, et al. The association between symptomatic delayed cerebral infarction and serum adhesion molecules in aneurysmal subarachnoid hemorrhage. Neurosurgery 2011; 68:1611-1617.
36. Thome C, Seiz M, Schubert GA, et al. Nicardipine pellets for the prevention of cerebral vasospasm. Acta Neurochir Suppl 2011; 110:209-211.
37. Kasuya H. Clinical trial of nicardipine prolonged-release implants for preventing cerebral vasospasm: multicenter cooperative study in Tokyo. Acta Neurochir Suppl 2011; 110:165-167.
38. Barth M, Pena P, Seiz M, et al. Feasibility of intraventricular nicardipine prolonged release implants in patients following aneurysmal subarachnoid haemorrhage. Br J Neurosurg 2011; 25:677-683.
39. Kramer AH, Fletcher JJ. Locally-administered intrathecal thrombolytics following aneurysmal subarachnoid hemorrhage: a systematic review and metaanalysis. Neurocrit Care 2011; 14:489-499.
40. Mori K, Yamamoto T, Miyazaki M, et al. Effect of intrathecal magnesium sulfate solution injection via a microcatheter in the cisterna magna on cerebral vasospasm in the canine subarachnoid haemorrhage model. Br J Neurosurg 2011. doi 10.3109/02688697.2011.591948.
41. Mori K, Yamamoto T, Miyazaki M, et al. Optimal cerebrospinal fluid magnesium ion concentration for vasodilatory effect and duration after intracisternal injection of magnesium sulfate solution in a canine subarachnoid hemorrhage model. J Neurosurg 2011; 114:1168-1175.
42. Wolf S. Routine management of volume status after aneurysmal subarachnoid Hemorrhage. Neurocrit Care 2011; 15:275-280.
43. Chittiboina P, Conrad S, McCarthy P, et al. The evolving role of hemodilution in treatment of cerebral vasospasm: a historical perspective. World Neurosurg 2011; 75:660-664.
44. Naidech AM, Shaibani A, Garg RK, et al. Prospective, randomized trial of higher goal hemoglobin after subarachnoid hemorrhage. Neurocrit Care 2010; 13:313-320.
45. Appelboom G, Strozyk D, Hwang BY, et al. Bedside use of a dual aortic balloon occlusion for the treatment of cerebral vasospasm. Neurocrit Care 2010; 13:385-388.
46. Jun P, Ko NU, English JD, et al. Endovascular treatment of medically refractory cerebral vasospasm following aneurysmal subarachnoid hemorrhage. AJNR Am J Neuroradiol 2010; 31:1911-1916.
47. Kimball MM, Velat GJ, Hoh BL. Critical care guidelines on the endovascular management of cerebral vasospasm. Neurocrit Care 2011; 15:336-341.
48. Sehy JV, Holloway WE, Lin SP, et al. Improvement in angiographic cerebral vasospasm after intra-arterial verapamil administration. AJNR Am J Neuroradiol 2010; 31:1923-1928.
49. Albanese E, Russo A, Quiroga M, et al. Ultrahigh-dose intraarterial infusion of verapamil through an indwelling microcatheter for medically refractory severe vasospasm: initial experience. Clinical article. J Neurosurg 2010; 113:913-922.
50. Miley JT, Tariq N, Souslian FG, et al. Comparison between angioplasty using compliant and noncompliant balloons for treatment of cerebral vasospasm associated with subarachnoid hemorrhage. Neurosurgery 2011; 69(ONS Suppl 2):ons161-ons168.
51. Hanggi D, Steiger HJ. The influence of cisternal and ventricular lavage on cerebral vasospasm in patients suffering from subarachnoid hemorrhage: analysis of effectiveness. Acta Neurochir Suppl 2011; 110: 95-98.
52. Nakagomi T, Furuya K, Nagashima H, et al. Surgical procedure and results of cisternal washing therapy for the prevention of cerebral vasospasm following SAH. Acta Neurochir Suppl 2011; 110:105-109.
53. Bardutzky J, Witsch J, Juttler E, et al. EARLYDRAIN- outcome after early lumbar CSF-drainage in aneurysmal subarachnoid hemorrhage: study protocol for a randomized controlled trial. Trials 2011; 12:203.